Pfizer’s Exubera Receives Nicer Recommendations From U.K.’s NICE
This article was originally published in The Pink Sheet Daily
Executive Summary
The group recommends inhaled insulin for diabetes patients with problems finding injection sites and injection phobias.
You may also be interested in...
Exubera Adoption Not Recommended By U.K. Cost-Effectiveness Group
The National Institute for Health & Clinical Excellence says it needs more evidence on Pfizer’s inhaled insulin before it can recommend NHS coverage.
Pfizer Breathes Easy: FDA Approves Exubera
Pfizer's Exubera is the first inhaled insulin to clear FDA; labeling recommends lung function testing.
India Highlights "Public Interest" To Reign In Prices For Non-Scheduled Drugs
Dr. Reddy's, GSK, Ranbaxy and UCB among manufacturers that could see prices reduced under government order that reflects issues raised in Gleevec patent dispute.